

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)

Meeting – May 14, 2014 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. April 9, 2014 DUR Minutes – Vote
- B. April 9, 2014 DUR Recommendation Memorandum

Items to be presented by Dr. Muchmore, Chairman:

4. Action Item – Vote to Change Meeting Time and Location – See Appendix B

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

**5. Update of Medication Coverage Authorization Unit/
SoonerPsych Program Update – See Appendix C**

- A. Medication Coverage Activity for April 2014
- B. Pharmacy Help Desk Activity for April 2014
- C. SoonerPsych Program Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Ophthalmic Anti-Inflammatories – See Appendix D

- A. Introduction
- B. COP Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Lorzone™ (Chlorzoxazone) – See Appendix E

- A. COP Recommendations

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

**8. Action Item – Vote to Prior Authorize Farxiga™ (Dapagliflozin) and
Invokana™ (Canagliflozin) – See Appendix F**

- A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Luzu® (Luliconazole) – See Appendix G

- A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Zorvolex™ (Diclofenac) and Tivorbex™ (Indomethacin) – See Appendix H

- A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

11. Annual Review of Anticonvulsant Medications and 30-Day Notice to Prior Authorize Trokendi XR™ (Topiramate ER), Aptiom® (Elis carbazepine Acetate), and Qudexy™ XR (Topiramate ER) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Anticonvulsants
- C. Prior Authorization of Anticonvulsants
- D. Market News and Updates
- E. COP Recommendations
- F. Utilization Details
- G. Product Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

12. 30-Day Notice to Prior Authorize Sovaldi™ (Sofosbuvir), Olysio™ (Simeprevir), Victrelis® (Boceprevir), and Incivek® (Telaprevir) – See Appendix J

- A. Introduction
- B. Utilization Details Sovaldi™ and Olysio™
- C. Market News and Updates
- D. Medication Summaries
- E. COP Recommendations
- F. Utilization Details
- G. Product Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

13. FDA and DEA Updates – See Appendix K

14. Future Business

- A. Annual Reviews
- B. New Product Reviews

15. Adjournment